Publicacións nas que colabora con Alvaro Mena de Cea (7)
2023
-
Renal profile of patients treated with elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort
European Journal of Hospital Pharmacy, Vol. 30, Núm. 4, pp. 221-226
2022
-
Discontinuation due to neuropsychiatric adverse events with efavirenz-and dolutegravir-based antiretroviral therapy: a comparative real-life study
European Journal of Hospital Pharmacy, Vol. 29, Núm. 4, pp. 207-211
-
Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV
AIDS, Vol. 36, Núm. 5, pp. 691-695
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Effectiveness and safety of sofosbuvir/velpatasvir ± ribavirin vs glecaprevir/pibrentasvir in genotype 3 hepatitis C virus infected patients
European Journal of Hospital Pharmacy, Vol. 27, Núm. 1 e, pp. E41-E47
2019
-
Teleconsultation for the Pharmaceutical Care of HIV Outpatients in Receipt of Home Antiretrovirals Delivery: Clinical, Economic, and Patient-Perceived Quality Analysis
Telemedicine and e-Health, Vol. 25, Núm. 5, pp. 399-406
-
Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine
Basic and Clinical Pharmacology and Toxicology, Vol. 124, Núm. 4, pp. 479-490